Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6–11 years with severe atopic dermatitis
| Autor: | Carsten Flohr, Alan D Irvine, Michael J Cork, Eric L Simpson, Andreas Wollenberg, Mette Deleuran, Amy Praestgaard, Ryan B Thomas, Ana B Rossi |
|---|---|
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Flohr, C, Irvine, A D, Cork, M J, Simpson, E L, Wollenberg, A, Deleuran, M, Praestgaard, A, Thomas, R B & Rossi, A B 2023, ' Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6-11 years with severe atopic dermatitis ', British Journal of Dermatology . https://doi.org/10.1093/bjd/ljad124 |
| ISSN: | 1365-2133 0007-0963 |
| Popis: | This was a post-hoc analysis of patient-reported outcomes from the LIBERTY AD PEDS randomized, double-blind, placebo-controlled, phase 3 trial of dupilumab + topical corticosteroids (TCS) in 367 children aged 6–11 years with severe atopic dermatitis (AD). At week 16, significantly more dupilumab-treated patients vs placebo achieved a Patient-Oriented Eczema Measure (POEM) score of 0/1 (“clear skin”/“almost clear skin”), and significantly more reported Children’s Dermatology Life Quality Index (CDLQI) scores of 0/1 (“no effect on life”). Significantly more patients achieved a minimal clinically important difference (≥6 point reduction) in POEM and in CDLQI. Dupilumab (vs placebo) + TCS resulted clinically meaningful improvements in patients’ assessment of AD symptoms and quality of life. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|